Table 5.
Prognostic Factors for DFS/PFS and OS for the Patients in PD-L1-Negative Group
| Characteristics | DFS/PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (years) | 0.952 (0.876–1.034) | 0.245 | 0.912 (0.809–1.027) | 0.129 | ||||
| Gender (Male/Female) |
1.149 (0.308–4.280) | 0.836 | ||||||
| TNM stage (I–II/III–IV) |
8.268 (2.172–31.465) | 0.002 | 8.268 (2.172–31.465) | 0.002 | 11.372 (1.008–128.254) | 0.049 | ||
| Tumor size (mm) | 1.052 (0.985–1.123) | 0.132 | ||||||
| Tumor differentiation Well/Moderate or poor |
0.923 (0.186–4.574) | 0.922 | 6.691 (0.598–74.914) | 0.123 | ||||
| CEA (ng/mL) | 1.014 (1.004–1.025) | 0.006 | 1.023 (1.008–1.038) | 0.003 | 1.022 (1.006–1.039) | 0.006 | ||
| Ki67 | 1.028 (1.001–1.056) | 0.043 | 1.050 (1.007–1.095) | 0.022 | ||||
| PD-1 | 1.053 (0.774–1.433) | 0.742 | 1.109 (0.633–1.943) | 0.719 | ||||
| GLUT1 | 1.126 (0.787–1.612) | 0.516 | 0.970 (0.536–1.758) | 0.921 | ||||
| HK-II | 1.036 (0.747–1.437) | 0.833 | 1.032 (0.585–1.819) | 0.914 | ||||
| SUVmax | 1.192 (1.047–1.356) | 0.008 | 1.363 (1.083–1.716) | 0.008 | ||||
| MTV (cm3) | 1.102 (0.936–1.296) | 0.244 | 1.207 (0.975–1.495) | 0.084 | ||||
| TLG (cm3) | 1.011 (1.000–1.022) | 0.050 | 1.018 (1.004–1.032) | 0.013 | ||||
Abbreviations: DFS, disease-free survival; PFS, progression-free survival; OS, overall survival; PD-L1, programmed death ligand-1; CEA, carcino-embryonic antigen; PD-1, programmed death-1; GLUT-1, glucose transporter 1; HK-II, hexokinase II; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis.